Radiopharm Theranostics is at the forefront of developing innovative radiopharmaceutical technologies aimed at improving cancer diagnosis and treatment. Their proprietary platform, Nano-mAbs, utilizes genetically engineered single domain antibodies derived from camelids, which are labeled with radioisotopes for both therapeutic and diagnostic purposes. This dual approach allows for precise targeting of oncological diseases, particularly in cancers expressing HER-2 and PD-L1. The technology has demonstrated promising results in clinical trials, showcasing high specificity and safety in imaging, as well as the potential for effective therapeutic applications using isotopes like Re-188 and Lu-177.

In addition to Nano-mAbs, Radiopharm Theranostics is advancing several other radiopharmaceutical candidates, including Pivalate, AVβ6 Integrin, and PSA-mAb. Pivalate, an 18F-FPIA radiotracer, has shown superior imaging capabilities in prostate and brain cancers compared to traditional methods. AVβ6 Integrin targets a specific cell surface protein prevalent in challenging cancers, offering potential for early detection through PET imaging. Meanwhile, PSA-mAb is designed to target prostate-specific antigen in prostate cancer, demonstrating significant therapeutic potential with sustained tumor regression in preclinical studies. Collectively, these technologies represent a significant leap forward in the field of cancer theranostics, aiming to enhance patient outcomes through more accurate diagnostics and targeted therapies.

Australia

Radiopharm Theranostics is developing a world-class platform of radiopharmaceutical and nuclear medicine products for both diagnostic and therapeutic applications. The company is focused on innovating the way we see and treat cancer, with a particular emphasis on HER-2 cancers. Radiopharm Theranostics has a strong team of executives and board members, and is actively engaged in investor relations and corporate governance. The company has also launched a joint venture with MD Anderson to focus on novel radiopharmaceuticals.

Radiopharm Theranostics

Company Details